Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from Organon ( (OGN) ) is now available.
Organon announced its financial results for the fourth quarter and full year of 2024, reporting annual revenue of $6.4 billion, a 2% increase as-reported, and a 3% increase at constant currency. Despite challenges like the loss of exclusivity for Atozet in certain markets, the company aims for continued growth in 2025, with a revenue projection of $6.125 to $6.325 billion. The fourth quarter of 2024 showed flat revenue compared to the previous year, with notable performance in women’s health due to Nexplanon growth and competitive pressures on biosimilars. The company’s net income saw a decrease due to a one-time tax benefit in 2023, while non-GAAP adjusted net income remained stable.
More about Organon
Organon operates in the healthcare industry, focusing on women’s health, biosimilars, and established brands. The company provides a range of products in these areas, with a market focus on constant currency revenue growth and managing operating costs.
YTD Price Performance: -1.74%
Average Trading Volume: 3,234,375
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.79B
Learn more about OGN stock on TipRanks’ Stock Analysis page.
